Dr. Scott Eggener on Grade Group 1 Prostate Cancer
Dr. Scott Eggener, Director, High Risk and Advanced Prostate Cancer Clinic, UChicago Medicine, provides an overview of the advancements and patient perspectives of grade group 1 prostate cancer.
▶︎
Surgery or Radiotherapy for Prostate Cancer? Here's What the Evidence Shows
▶︎
Why Gleason 6 Prostate Cancer is Not Cancer with Dr Scott Eggener EP 87
▶︎
Gleason 6 #ProstateCancer 101 | #MarkScholzMD #AlexScholz #PCRI
▶︎
Gleason 3+4 Prostate Cancer
▶︎
Gleason 6 prostate cancer | Why we should rename it (and why we can't)!
▶︎
Hormone Therapy & Side Effects For High-Risk (Gleason 8) #ProstateCancer | Mark Scholz, MD #PCRI
▶︎
Is Gleason 6 Really Prostate Cancer - A Debate!
▶︎
Navigating Lung Health & Pulmonary Care | 08.19.25 | Lung Cancer Living Room®
▶︎
Do Prostate Biospies Spread #ProstateCancer? | #MarkScholzMD #AlexScholz #PCRI
▶︎
Most Men with Prostate Cancer are Choosing This Instead
▶︎
Gleason 7 (4+3) #prostatecancer Treatments and Side Effects | #markscholzmd | PCRI
▶︎
Gleason 3+4 vs 4+3: Which One Is More Dangerous?
▶︎
Managing an Elevated PSA: Avoiding Unnecessary Prostate Biopsies
▶︎
High-risk prostate cancer: what patients and physicians should know in 2026
▶︎
Radiation therapy for prostate cancer: the basics
▶︎
A future with No Prostate Biopsies with Mark Emberton, MD EP 86
▶︎
Hormonal Therapy for Prostate Cancer
▶︎
Newly Diagnosed Stage 4 #ProstateCancer | #MarkScholzMD #AlexScholz #PCRI
▶︎
Novel Treatments Strategies for Prostate Cancer
▶︎